Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 1/20 | 0.52 |
| ▸ | GRM5 | P41594 | 1/20 | 0.52 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.52 |
| ▸ | NPC1 | O15118 | 2/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | CNR1 | P21554 | 1/20 | 0.43 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.42 |
| ▸ | MLYCD | O95822 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22387736 | 0.81 | HDAC1 (0.56) | NPC1KMT2ARAB9A | |
| SCHEMBL9906415 | 0.81 | EPHX2 (0.44) | NPC1KMT2ACNR1RAB9A | |
| SCHEMBL17660295 | 0.80 | MLYCD (0.46) | NPC1KMT2AMLYCDRAB9A | |
| SCHEMBL19164278 | 0.80 | ANO1 (0.44) | NPC1KMT2ARAB9A | |
| SCHEMBL14186811 | 0.78 | CHRM2 (0.56) | CHRM2GRM5SIGMAR1CNR1TRPA1 | |
| SCHEMBL16478648 | 0.78 | CNR1 (0.57) | CHRM2GRM5SIGMAR1NPC1KMT2A | |
| SCHEMBL13164714 | 0.78 | GRM5 (0.56) | CHRM2GRM5SIGMAR1NPC1KMT2A | |
| SCHEMBL1397745 | 0.78 | MAPK1 (0.61) | NPC1KMT2ARAB9A | |
| SCHEMBL3486437 | 0.78 | KMT2A (0.44) | NPC1KMT2ARAB9A | |
| SCHEMBL9906417 | 0.77 | CNR1 (0.43) | NPC1KMT2AMEN1CNR1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230183229-A1 | Compounds | SYGNATURE DISCOVERY LIMITED (GB) | 2023-06-15 | — | — | US | disclosed |
| US-8987268-B2 | Pyrrolopyridazine JAK3 inhibitors and their use for the treatment of inflammatory and autoimmune diseases | BRISTOL-MYERS SQUIBB COMPANY (US) | 2015-03-24 | — | — | US | disclosed |
| US-20140011800-A1 | PYRROLOPYRIDAZINE JAK3 INHIBITORS AND THEIR USE FOR THE TREATMENT OF INFLAMMATORY AND AUTOIMMUNE DISEASES | BRISTOL-MYERS SQUIBB COMPANY | 2014-01-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230183229-A1 | Compounds | UGT1A1, CYP1A1, CYP1B1 | CHRM2 3655/4885GRM5 3812/4885SIGMAR1 1258/4885 |
| US-20140011800-A1 | PYRROLOPYRIDAZINE JAK3 INHIBITORS AND THEIR USE FOR THE TREATMENT OF INFLAMMATORY AND AUTOIMMUNE DISEASES | JAK3, JAK1, JAK2 | CHRM2 4853/4885GRM5 1536/4885SIGMAR1 4192/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.